Growth in the market of High Potency APIs is considered to be the single largest and important trend that deserves attention by all players in this field. All highly potent APIs must be produced under conditions that protect any API substances from contamination and the inadvertent carryover of a different product being previously or simultaneously manufactured. To accomplish this task, there is a continued need to focus on the development of production and handling methods that will be either single-use systems and/or new technologies. The focus is on the improvement upon today’s product protection of the API from cross contamination from other HPAPI produced at the facility or site. (Source: totalbiopharma.com, The single largest trend in the HPAPI space, 2014)Five years ago the drivers for containment were almost strictly for protecting the operators for exposure of the compound. Since then, containing the product to minimise the risk cross contamination in the facility has become equally important. SMi's masterclass hosted by SafeBridge & ILC Dover LP will assess how to improve understanding on containment and identifying how to minimise the risks of exposure. Key benefits to this masterclass are: • Gain an accurate understanding of pharmaceutical compound hazards • Evaluate flexible vs. hard wall containment • Review practical case studies using different containment methods to create standardisation • Assess facility design elements to ensure confidence in meeting containment objectives